Suzuki Kei, Oda Hiroyasu, Sugawara Yumiko, Masuya Masahiro, Nakase Kazunori, Fujioka Masaki, Imai Hiroshi, Katayama Naoyuki
Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan.
Intern Med. 2013;52(5):611-5. doi: 10.2169/internalmedicine.52.8933. Epub 2013 Mar 1.
We herein report the case of a 77-year-old woman who developed acute thrombocytopenia during the 23rd cycle of modified FOLFOX therapy. She developed a hypersensitivity reaction with nasal bleeding. The chemotherapy infusion was immediately discontinued. The patient's symptoms resolved with discontinuation of chemotherapy and the administration of supportive therapy. A complete blood count showed severe thrombocytopenia, and oxaliplatin-induced thrombocytopenia was diagnosed. The patient was admitted to the hospital, and the thrombocytopenia was corrected with a platelet transfusion followed by prednisolone. She was discharged after one week without requiring additional platelet transfusions. With the widespread use of oxaliplatin, the risk of oxaliplatin-induced acute thrombocytopenia should be considered an acute onset hematological emergency.
我们在此报告一例77岁女性患者，她在接受改良FOLFOX方案化疗的第23周期时出现急性血小板减少症。她出现了伴有鼻出血的过敏反应。化疗输注立即停止。患者的症状在化疗停止并给予支持治疗后得到缓解。全血细胞计数显示严重血小板减少，诊断为奥沙利铂诱导的血小板减少症。患者入院，通过输注血小板随后给予泼尼松龙纠正了血小板减少症。一周后她出院，无需额外的血小板输注。随着奥沙利铂的广泛使用，奥沙利铂诱导的急性血小板减少症的风险应被视为一种急性发作的血液学急症。
